G. Song

Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.

Stephen X. Zhang, K. Neville, T. Klingebiel, 2018, The Lancet. Haematology.

Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study

K. Venkatakrishnan, D. Mould, C. Endres, 2019, Clinical pharmacology and therapeutics.

Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Wei Li, Jun Zhu, X. Ke, 2021, Expert review of hematology.

DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study.

H. Colman, D. Reardon, Y. Arakawa, 2022, Journal of Clinical Oncology.

Brigatinib vs Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3).

Geoffrey Liu, J. Yang, S. Popat, 2021, Future oncology.

Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens

K. Venkatakrishnan, D. Mould, A. Suri, 2020, Journal of clinical pharmacology.